Scientists at Queen Mary University of London have developed a new prostate cancer blood test that promises a significant increase in accuracy compared to current blood tests. If verified in larger ...
Paradigm and Translational Drug Development (TD2) today announced a partnership under which Paradigm will provide their PCDx test to TD2's affiliated oncology provider networks. PCDx is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results